Die prognostische Bedeutung des Tumorvolumens beim Osteosarkom unter neoadjuvanter Chemotherapie
Nosheen Rehan, K. Winkler, K. Helmke(Universität Hamburg), P. Bieling(Universität Hamburg), Nicola Baldini(Istituto Ortopedico Rizzoli), U. Heise, Peter Winkler(Paracelsus Medical University), N. Fuchs, R. Maas(Universität Hamburg)
Cited by 16
Related Papers
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
|Journal of Clinical Oncology|2005|654
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
Osteosarcoma of the Pelvis: Experience of the Cooperative Osteosarcoma Study Group
|Journal of Clinical Oncology|2003|344
Influence of cranioplasty on postural blood flow regulation, cerebrovascular reserve capacity, and cerebral glucose metabolism
|Journal of neurosurgery|2000|340